Immunic Inc Dossier - Source-backed chat

Immunic Inc

IMUXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.25

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $8.64Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $117.9M

Enterprise Value −$68.7M

Shares Outstanding 13.6M diluted

Next Earnings Date16 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Immunic, Inc. is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and chronic inflammatory diseases. The company's lead asset, vidofludimus calcium (IMU-838), is an oral Nurr1 activator and DHODH inhibitor currently in twin Phase 3 trials (ENSURE-1 and ENSURE-2) for relapsing multiple sclerosis (RMS), with highly anticipated top-line data expected by the end of 2026. Backed by a robust cash position of $186.6 million as of Q1 2026, which provides a runway into late 2027, Immunic is well-positioned to reach its key clinical catalysts without immediate dilution risk. The recent appointment of experienced neurology drug developer Dr. Michael A. Panzara as Chief Medical Officer further strengthens the company's execution capabilities as it transitions toward potential commercialization.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$19.00

Mean target$43.22

High · most bullish analyst$85.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.5015%

The Phase 3 ENSURE trials fail to meet their primary endpoints or reveal unexpected safety concerns, severely damaging the clinical viability of vidofludimus calcium. The company is forced to pivot to its earlier-stage pipeline (such as IMU-856), leading to a significant destruction of shareholder value and an urgent need for dilutive financing.

Base CaseCentral scenario

$43.2265%

Matches the consensus mean

The twin Phase 3 ENSURE trials in RMS deliver positive top-line data by the end of 2026, demonstrating competitive efficacy and a superior safety/tolerability profile compared to existing oral MS therapies. This triggers the planned NDA submission in mid-2027, paving the way for regulatory approval in 2028. The cash runway remains sufficient to support operations through these milestones.

Bull CaseUpside scenario

$40.0025%

The Phase 3 ENSURE trials in RMS deliver exceptionally strong efficacy data by the end of 2026, establishing vidofludimus calcium as a best-in-class oral therapy. Rapid NDA approval in 2028 is followed by a highly successful commercial launch led by the newly appointed commercial leadership team. Concurrently, a strategic partnership or licensing deal is secured for IMU-856, providing non-dilutive funding and validating the broader platform.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Highly anticipated Phase 3 top-line data readout for lead asset vidofludimus calcium in RMS expected by the end of 2026.
Strong balance sheet with $186.6 million in cash as of March 31, 2026, extending the operational runway into late 2027.
Strengthened leadership team with the appointment of Dr. Michael A. Panzara as Chief Medical Officer, bringing deep MS clinical development expertise.
Potential for broad platform expansion across progressive MS and gastrointestinal diseases (celiac disease, ulcerative colitis).

Key Investment Risks

High clinical development risk inherent in Phase 3 trials, where failure to meet primary endpoints would invalidate the core investment thesis.
Pre-revenue status with ongoing high cash burn, making the company dependent on future capital raises or partnerships to fund commercialization.
Intense competition in the multiple sclerosis market from established oral and injectable therapies.

Thesis Invalidation Triggers

Failure of the twin Phase 3 ENSURE trials to meet their primary efficacy endpoints in RMS.
Emergence of serious adverse safety signals for vidofludimus calcium during clinical trials.
Inability to secure strategic partnerships or additional financing before the cash runway expires in late 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.